CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dicerna Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dicerna Pharmaceuticals Inc
75 Hayden Avenue
Phone: (617) 621-8097p:617 621-8097 LEXINGTON, MA  02421  United States Ticker: DPLDPL
This company was Merged or Acquired on 12/28/2021.
This company ceased filing statements with the SEC on 1/10/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The Company's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202112/31/2020YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board J. KevinBuchi 66 1/24/2019 8/13/2018
President, Chief Executive Officer, Director Douglas M.Fambrough 52 5/1/2010 4/1/2007
Chief Financial Officer Douglas W.Pagan 49 5/26/2020 5/26/2020
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Dicerna Germany GmbH
Dicerna Secruity Corporation
Discerna EU Limited
Discerna Ireland Limited
DPL
DRNA

General Information
Number of Employees: 302 (As of 12/31/2020)
Outstanding Shares: 77,888,932 (As of 11/4/2021)
Shareholders: 6
Stock Exchange: NASD
Federal Tax Id: 205993609
Fax Number: (617) 612-6298
Email Address: contact@dicerna.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024